Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 10/20 | 0.52 |
| ▸ | HCRTR1 | O43613 | 9/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | WDR5 | P61964 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 5/20 | 0.46 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1849280 | 0.93 | HCRTR2 (0.57) | HCRTR2HCRTR1CYP3A4HTR2AKCNH2 | |
| SCHEMBL3486115 | 0.82 | HCRTR2 (0.61) | HCRTR2HCRTR1CYP3A4HTR2AKCNH2 | |
| SCHEMBL13498691 | 0.80 | HCRTR2 (0.70) | HCRTR2HCRTR1CYP3A4HTR2AKCNH2 | |
| SCHEMBL1854206 | 0.78 | AXL (0.47) | HCRTR2HCRTR1CYP3A4HTR2AGAA | |
| SCHEMBL2275627 | 0.77 | HCRTR2 (0.70) | HCRTR2HCRTR1CYP3A4HTR2AKCNH2 | |
| SCHEMBL3487028 | 0.76 | HCRTR2 (0.60) | HCRTR2HCRTR1CYP3A4HTR2AKCNH2 | |
| SCHEMBL2277880 | 0.74 | HCRTR2 (0.65) | HCRTR2HCRTR1CYP3A4HTR2AKCNH2 | |
| SCHEMBL3485359 | 0.74 | HCRTR2 (0.55) | HCRTR2HCRTR1CYP3A4HTR2AKCNH2 | |
| SCHEMBL13498698 | 0.74 | HCRTR2 (0.69) | HCRTR2HCRTR1CYP3A4HTR2AKCNH2 | |
| SCHEMBL28398425 | 0.73 | LMNA (0.56) | HCRTR2HCRTR1CYP3A4HTR2AKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035931-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-02-11 | — | — | US | claimed |
| EP-2323985-B1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2017-01-11 | — | — | EP | disclosed |
| US-8349872-B2 | Tripyridyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349872-B2 | Tripyridyl carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2013-01-08 | — | — | US | disclosed |
| WO-2010017260-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2010-02-11 | — | — | WO | disclosed |
| US-20100035931-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-02-11 | — | — | US | disclosed |
| US-20100035931-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME LLC | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035931-A1 | TRIPYRIDYL CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NTSR2 | HCRTR2 1/4885HCRTR1 2/4885CYP3A4 4148/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.